109669-45-6

Basic information

• Product Name: Tributyl(5,6-dihydro-4H-pyran-2-yl)stannane
• Synonyms: 3,4-Dihydro-6-(tributylstannyl)-2H-pyran;Tributyl(5,6-dihydro-4H-pyran-2-yl)stannane
• CAS NO: 109669-45-6
• Molecular Formula: C₁₇H₃₄OSn
• Molecular Weight: 373.16126
• Mol File: 109669-45-6.mol

Chemical Properties

• Boiling Point: 378.3±52.0 °C(Predicted)
• Flash Point: >110℃
• Appearance: /
• Density: 1.119 g/mL at 25 °C
• Refractive Index: n20/D1.495
• CAS DataBase Reference: Tributyl(5,6-dihydro-4H-pyran-2-yl)stannane(CAS DataBase Reference)
• NIST Chemistry Reference: Tributyl(5,6-dihydro-4H-pyran-2-yl)stannane(109669-45-6)
• EPA Substance Registry System: Tributyl(5,6-dihydro-4H-pyran-2-yl)stannane(109669-45-6)

Safety Data

• Hazard Codes: T,N
• Statements: 21-25-36/38-48/23/25-50/53
• Safety Statements: 36/37/39-45-60-61
• RIDADR: UN 2788 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 109669-45-6(Hazardous Substances Data)

Upstream product

• 110-87-2 3,4-dihydro-2H-pyran 
• 1461-22-9 tributyltin chloride 
• 594-19-4 tert.-butyl lithium 

Downstream Products

• 132093-61-9 (4S,9aR)-1,3-Dioxo-2-phenyl-2,3,7,8,9,9a-hexahydro-1H,4H-6-oxa-2,3a,9b-triaza-cyclopenta[a]naphthalene-4-carboxylic acid methyl ester 
• 132093-53-9 6-o-Tolyl-3,4-dihydro-2H-pyran 
• 149795-91-5 6-((E)-Styryl)-3,4-dihydro-2H-pyran 
• 59792-14-2 1-Phenyl-1-(5.6-dihydro-4H-2-pyranyl)-ethylen 
• 304669-40-7 (2-(3,4-dihydro-2H-pyran-6-yl)phenyl)methanol 
• 57455-06-8 3-iodobenzylalcohol 
• 304669-39-4 3,4-dihydro-6-(2-nitrophenyl)-2H-pyrane 
• 208464-78-2 C₂₅H₂₆N₂O₂ 

Relevant articles and documents

Ynamide Carbopalladation: A Flexible Route to Mono-, Bi- and Tricyclic Azacycles

Bromoenynamides represent precursors to a diversity of azacycles by a cascade sequence of carbopalladation followed by cross-coupling/electrocyclization, or reduction processes. Full details of our investigations into intramolecular ynamide carbopalladation are disclosed, which include the first examples of carbopalladation/cross-coupling reactions using potassium organotrifluoroborate salts; and an understanding of factors influencing the success of these processes, including ring size, and the nature of the coupling partner. Additional mechanistic observations are reported, such as the isolation of triene intermediates for electrocyclization. A variety of hetero-Diels-Alder reactions using the product heterocycles are also described, which provide insight into Diels-Alder regioselectivity.

BETA-SECRETASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.

5-CYCLO INDOLE COMPOUNDS AS 5-HT1D RECEPTOR LIGANDS

Described herein are compounds selective for a 5-HT1D-like receptor, which have general formula (I), wherein A is selected from a six-membered, non-aromatic, optionally substituted carbocycle and a six-membered, non-aromatic, optionally substituted heterocycle having one or two heteroatoms selected from O, S, SO, SO2 and NR; R is selected from H and OH; n is 0 or 1 as permitted by chemical structure; R is selected from CRRCH2NRR or a group of formula (II), (III) or (IV); R is selected from H and benzoyl; R is selected from H, loweralkyl, benzyl, loweralkylcarbonyl, loweralkylaminocarbonyl; loweralkylaminothiocarbonyl, loweralkanoyl, loweralkylaminoimide and loweralkoxy-substituted loweralkylene; R and R are independently selected from H, loweralkoxy and hydroxy; R and R are independently selected from H and loweralkyl or R and R form an alkylene bridge which, together with the nitrogen atom to which they are attached, creates an optionally substituted 3- to 6-membered ring; ----- denotes a single or double bond; and R, R and R are independently selected from H and loweralkyl. Also described is the use of these compounds as pharmaceuticals to treat indications where stimulation of a 5-HT1D-like receptor is implicated, such as migraine.

Alphalosporins and 1-carba-1-dethia cephalosporins

Compound of formula (I) or salts thereof wherein R1 is hydrogen, methoxy or formamido; R2 is an acyl group; CO2 R3 is a carboxy group or a carboxylate anion, or R3 is a readily removable carboxy protecting group or a pharmaceutically acceptable salt-forming group or in vivo hydrolysable ester group; R4 represents hydrogen or up to four substituents; X is S, SO, SO2 or CH2 ; Y is O, S, SO or SO2 ; n is 0 or 1; m is 1 or 2; and wherein in the (a) ring system the dotted line indicates that one pair of adjacent ring carbon atoms is joined by a C=C double bond. These compounds have antibacterial activity.